2
项与 CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd) 相关的临床试验 / Not yet recruiting临床1/2期 Phase 1/Phase 2 Study of Sequential Chimeric Antigen Receptor T Cell Targeting at CD19 and CD22 B-cell Antigens Treating Refractory or Relapsed B-cell Lymphoma Patients
This is a single arm study to evaluate the efficacy and safety of Sequential CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma.
Donor fully human CD19/CD22 dual target CAR T cells combined with allogeneic hematopoietic stem cell transplantation for the treatment of adult refractory/relapsed B-cell lymphoma. Single-center, open, non-randomized, single-arm clinical trial
100 项与 CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd) 相关的临床结果
100 项与 CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd) 相关的转化医学
100 项与 CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd) 相关的专利(医药)
100 项与 CD19 and CD22 targeted CAR-T cells(Kecellitics Biotech Company Ltd) 相关的药物交易